• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lifshitz Law PLLC Announces Investigations of EQRX, RVMD, NEWR, and RETA

    8/5/23 8:13:00 PM ET
    $EQRX
    $NEWR
    $RETA
    $RVMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $EQRX alert in real time by email

    NEW YORK, Aug. 05, 2023 (GLOBE NEWSWIRE) --

    EQRx, Inc. (NASDAQ:EQRX)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of EQRX to Revolution Medicines, Inc. Under the terms of the proposed merger, EQRX shareholders will receive the number of shares of Revolution Medicines, Inc. stock equal to the sum of ~7.69M Revolution Medicines, Inc. shares plus a number of shares equal to $870M divided by a price that is a 6% discount to the 5-day volume-weighted average Revolution Medicines Inc. share price measured in close proximity to the stockholder vote.

    If you are an EQRX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

    Revolution Medicines, Inc. (NASDAQ:RVMD)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of EQRx, Inc. to RVMD. Under the terms of the proposed merger, EQRx, Inc. shareholders will receive the number of shares of RVMD stock equal to the sum of ~7.69M RVMD shares plus a number of shares equal to $870M divided by a price that is a 6% discount to the 5-day volume-weighted average RVMD share price measured in close proximity to the stockholder vote.

    If you are a RVMD investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

    New Relic, Inc. (NYSE:NEWR)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of NEWR to Francisco Partners and TPG Inc. for $87.00 per share in cash for each share of NEWR common stock owned.

    If you are a NEWR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

    Reata Pharmaceuticals, Inc. (NASDAQ:RETA)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of RETA to Biogen Inc. for $172.50 per share in cash for each share of RETA common stock owned.

    If you are a RETA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

    ATTORNEY ADVERTISING.© 2023 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

    Contact:

    Joshua M. Lifshitz, Esq.

    Lifshitz Law PLLC

    Phone: 516-493-9780

    Facsimile: 516-280-7376

    Email: info@lifshitzlaw.com



    Get the next $EQRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EQRX
    $NEWR
    $RETA
    $RVMD

    CompanyDatePrice TargetRatingAnalyst
    Revolution Medicines Inc.
    $RVMD
    5/22/2026$151.00Mkt Perform
    Bernstein
    Revolution Medicines Inc.
    $RVMD
    5/18/2026$179.00Buy
    Truist
    Revolution Medicines Inc.
    $RVMD
    3/16/2026Buy
    Jefferies
    Revolution Medicines Inc.
    $RVMD
    2/27/2026$145.00Buy
    UBS
    Revolution Medicines Inc.
    $RVMD
    11/18/2025$75.00Outperform
    Wolfe Research
    Revolution Medicines Inc.
    $RVMD
    11/3/2025$77.00Outperform
    RBC Capital Mkts
    Revolution Medicines Inc.
    $RVMD
    10/21/2025$90.00Outperform
    Mizuho
    Revolution Medicines Inc.
    $RVMD
    10/16/2025$85.00Buy
    Stifel
    More analyst ratings

    $EQRX
    $NEWR
    $RETA
    $RVMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schroeder Thilo bought $59,999,962 worth of shares (1,304,347 units at $46.00) (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    12/9/24 4:15:16 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EQRX
    $NEWR
    $RETA
    $RVMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SKYCLARYS issued to REATA PHARMACEUTICALS INC

    Submission status for REATA PHARMACEUTICALS INC's drug SKYCLARYS (ORIG-1) with active ingredient OMAVELOXOLONE has changed to 'Approval' on 02/28/2023. Application Category: NDA, Application Number: 216718, Application Classification: Type 1 - New Molecular Entity

    2/28/23 5:14:09 PM ET
    $RETA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQRX
    $NEWR
    $RETA
    $RVMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

    REDWOOD CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that four oral and poster presentations highlighting data from its RAS(ON) pipeline will be featured at the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress, taking place July 1–4, 2026 in Munich, Germany. The program will include two oral presentations from Phase 1/2 trials evaluating zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination regimens for patients with metastatic RAS G12D pancreatic ductal adenocarcinoma (PDAC). These

    6/24/26 7:31:08 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

    REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 305, a global, randomized Phase 3 clinical trial evaluating zoldonrasib in combination with standard of care chemotherapy as a first line treatment in patients with metastatic RAS G12D pancreatic ductal adenocarcinoma (PDAC). "Pancreatic cancer is a RAS-driven disease, and we recently reported that daraxonrasib, our RAS(ON) multi-selective inhibitor, significantly improved overall survival, progression-free survival, response rates, and prese

    6/23/26 8:00:00 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.

    Steve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution of strategy REDWOOD CITY, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Steve Kelsey, M.D., FRCP, FRCPath, president, research and development, will transition into the role of senior advisor to the chief executive officer, effective July 1, 2026. Dr. Kelsey plans to retire from his employment with the company on January 4, 2027, at wh

    6/22/26 8:00:00 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EQRX
    $NEWR
    $RETA
    $RVMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bernstein initiated coverage on Revolution Medicines with a new price target

    Bernstein initiated coverage of Revolution Medicines with a rating of Mkt Perform and set a new price target of $151.00

    5/22/26 8:49:34 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist resumed coverage on Revolution Medicines with a new price target

    Truist resumed coverage of Revolution Medicines with a rating of Buy and set a new price target of $179.00

    5/18/26 8:36:12 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies resumed coverage on Revolution Medicines

    Jefferies resumed coverage of Revolution Medicines with a rating of Buy

    3/16/26 9:35:47 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EQRX
    $NEWR
    $RETA
    $RVMD
    SEC Filings

    View All

    SEC Form 8-K filed by Revolution Medicines Inc.

    8-K - Revolution Medicines, Inc. (0001628171) (Filer)

    6/22/26 8:00:17 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Revolution Medicines Inc.

    144 - Revolution Medicines, Inc. (0001628171) (Subject)

    6/15/26 6:30:37 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Revolution Medicines Inc.

    144 - Revolution Medicines, Inc. (0001628171) (Subject)

    6/15/26 5:59:57 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EQRX
    $NEWR
    $RETA
    $RVMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Anders Jack exercised 20,000 shares at a strike of $18.56 and sold $3,366,604 worth of shares (20,000 units at $168.33) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    6/26/26 4:10:03 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Kim Lorence H. was granted 1,191 shares, increasing direct ownership by 2% to 74,281 units (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    6/23/26 5:57:09 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Borisy Alexis was granted 1,191 shares, increasing direct ownership by 0.05% to 2,340,075 units (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    6/23/26 5:52:08 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EQRX
    $NEWR
    $RETA
    $RVMD
    Leadership Updates

    Live Leadership Updates

    View All

    Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.

    Steve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution of strategy REDWOOD CITY, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Steve Kelsey, M.D., FRCP, FRCPath, president, research and development, will transition into the role of senior advisor to the chief executive officer, effective July 1, 2026. Dr. Kelsey plans to retire from his employment with the company on January 4, 2027, at wh

    6/22/26 8:00:00 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

    REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointment of Alan Sandler, M.D. into the newly created role of chief development officer, as well as the appointment of regional general managers in the U.S. and Europe. "I am delighted to welcome Alan as our chief development officer as we pursue our bold vision to develop new global standards of care for patients with RAS-addicted cancers," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. "As a physician-

    9/29/25 9:00:15 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer

    Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced the appointment of Rajiv Patni, M.D., as Executive Vice President, and Chief Research & Development Officer. Dr. Patni will report to Warren Huff, Chief Executive Officer, and will be responsible for overseeing the Company's research and development functions. "The team and I are excited to welcome Rajiv to Reata. His previous experience and his proven track record will help position the company for future growth," said Warren Huff, Chief Executive Officer. "His le

    6/13/23 6:45:00 AM ET
    $RETA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQRX
    $NEWR
    $RETA
    $RVMD
    Financials

    Live finance-specific insights

    View All

    Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

    REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that members of Revolution Medicines' senior management team will host a webcast on Sunday, May 31 at 7:00 pm ET to discuss positive results from the Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) following presentation of the data during the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. To listen to the live webcast, or access th

    5/21/26 4:05:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

    Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentationRASolute 302 data planned for submission to global regulatory authorities, including the U.S. Food and Drug AdministrationAACR 2026 presentations reinforce the breadth and strength of company's RAS(ON) portfolio, highlighting continued progress and novel approaches to RAS(ON) inhibitionStrengthened financial position with financings totaling $2.2 billion in gross proceedsRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 06, 2026 (GLOBE N

    5/6/26 4:02:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026

    REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live web

    4/29/26 4:05:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EQRX
    $NEWR
    $RETA
    $RVMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Revolution Medicines Inc.

    SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

    11/8/24 10:52:39 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

    SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

    2/14/24 6:30:27 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

    SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

    2/14/24 9:26:21 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care